Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.

about

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants.

P2860

Q47564027-867A9E6C-F2A0-4077-A1A6-394E6CA23B1B

P2860

Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.

Item

http://www.wikidata.org/entity/Q38625533

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.

@en

type

Item

label

Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.

@en

prefLabel

Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.

@en

P1476

Real-world costs of autosomal dominant polycystic kidney disease in the Nordics

@en

P2093

Eero Honkanen

http://www.w3.org/2001/XMLSchema#string

Hans Dieperink

http://www.w3.org/2001/XMLSchema#string

Jan Melin

http://www.w3.org/2001/XMLSchema#string

Johan Lundberg

http://www.w3.org/2001/XMLSchema#string

Kristian Selvig

http://www.w3.org/2001/XMLSchema#string

Linda Karlsson

http://www.w3.org/2001/XMLSchema#string

Oskar Eklund

http://www.w3.org/2001/XMLSchema#string

P2860

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study.

Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data.

Clinical practice. Autosomal dominant polycystic kidney disease.

Renal function and healthcare costs in patients with polycystic kidney disease.

End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases

Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference

The value of productivity: human-capital versus friction-cost method.

Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany.

Autosomal dominant polycystic kidney disease

P2888

s12913-017-2513-8

P304

560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12913-017-2513-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

D Eriksson

P577

2017-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28806944

http://www.w3.org/2001/XMLSchema#string

P921

autosomal dominant polycystic kidney disease

P932

5556351

http://www.w3.org/2001/XMLSchema#string

Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.

about

P2860

P2860

Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932